Journal profile · GENETICS & HEREDITY
Epigenomics
ISSN 1750-1911 · eISSN 1750-192X · TAYLOR & FRANCIS LTD · ENGLAND · Founded 2009
Epigenomics: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3.16; hybrid open access; APC charged, amount not published; median 117 days to acceptance (103 articles, last 24 months); community-reported acceptance: fairly easy; 127 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Epigenomics is published by TAYLOR & FRANCIS LTD and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Epigenetics and DNA Methylation, RNA modifications and cancer and Cancer-related molecular mechanisms research, together about 47.7% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Epigenomics is an international, peer-reviewed journal publishing high-quality, review articles, original research, study protocols, editorials and drug evaluation articles on vaccines. Please see the journal's Aims & Scope for information about its focus and peer-review policy.
From the journal's Aims & Scope
Research area (LetPub): GENETICS & HEREDITY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology31.7%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology9.4%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology6.5%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology5.7%
- Cancer-related gene regulationBiochemistry, Genetics and Molecular Biology5.4%
- Birth, Development, and HealthMedicine5.1%
- Genomics and Chromatin DynamicsBiochemistry, Genetics and Molecular Biology4.7%
- Histone Deacetylase Inhibitors ResearchBiochemistry, Genetics and Molecular Biology3.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Genetics & Heredity | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Genetics & Heredity | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Genetics & Heredity | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.16LetPub ·
- CiteScore 2026-06
- 3.9LetPub ·
- SJR 2026-06
- 0.77LetPub ·
- SNIP 2026-06
- 0.47LetPub ·
- h-index
- 44LetPub ·
- h-index
- 96OpenAlex ·
- i10-index
- 1,035OpenAlex ·
- 2-year mean citedness
- 3.21OpenAlex ·
- Self-citation rate
- 3.2%LetPub ·
- Share of gold OA articles
- 13.74%LetPub ·
Volume
- Articles per year
- 120LetPub ·
- Articles per year (publisher)
- 2,021Publisher website ·
Articles by year OpenAlex count · 1,979 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 83 | 81 | 28 |
| 2025 | 127 | 124 | 354 |
| 2024 | 113 | 89 | 655 |
| 2023 | 108 | 38 | 816 |
| 2022 | 106 | 38 | 1,054 |
| 2021 | 149 | 55 | 2,064 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
117 daysMedian, submission to acceptance · P25–P75 89 days – 148 days
- Acceptance to online
- median 9 days (103 articles)
- Submission to online
- median 128 days
- Sample
- 103 articles with submission and acceptance dates (241 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- over 12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Submission to final decision
- 21 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | Yes, amount not published | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare2 items from the author guidelines
- Abstract
- ≤ 200 words
- Reference style
- Numbered, in order of citation
Article types accepted1
- reviewAll standalone PLS articles are peer-reviewed, indexed, and published in over 100 Taylor & Francis journals. To help readers access them, they are available to …Length not stated
Policy excerpts from the journal's websiteConflicts of interest, Data availability, License & copyright, Open access, Peer review
- Conflicts of interest Financial and competing interests disclosure
Please include a disclosure of interest statement, using the subheading "Financial and competing interests disclosure." If you have no interests to declare, please state this (suggested wording: The authors report no conflicts of interest). For all NIH/Wellcome-funded papers, the grant number(s) must be included in the disclosure of interest statement. Read more on disclosing conflicts of interest…
Source ↗Publisher website ·- Data availability Data Sharing Policy
This journal applies the Taylor & Francis share upon reasonable request data sharing policy. Authors agree to make data and materials supporting the results or analyses presented in their paper available upon reasonable request. It is up to the author to determine whether a request is reasonable. Authors are required to cite any data sets referenced in the article and provide a Data Availability S…
Source ↗Publisher website ·- License & copyright Copyright options
Copyright allows you to protect your original material, and stop others from using your work without your permission. Taylor & Francis offers a number of different license and reuse options, including Creative Commons licenses when publishing open access. Read more on publishing agreements.
Source ↗Publisher website ·- Open access Open Access
You have the option to publish open access in this journal via our Open Select publishing program. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership and impact of your research. Articles published Open Select with Taylor & Francis typically receive 48% more citations and over 7 times as many downloads* com…
Source ↗Publisher website ·- Peer review Peer review
Taylor & Francis is committed to peer-review integrity and upholding the highest standards of review. Once your paper has been assessed for suitability by the editor, it will then be anonymously peer-reviewed by independent, anonymous expert referees, each delivering at least one report. If you have shared an earlier version of your Author’s Original Manuscript on a preprint server or registered y…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- TAYLOR & FRANCIS LTD
- Country or region
- ENGLAND
- Language
- English
- Founded
- 2009
- ISSN
- 1750-1911
- Electronic ISSN
- 1750-192X
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Epigenomics
What CAS zone is Epigenomics in?
In the 2025 upgraded edition of the CAS Journal Ranking, Epigenomics is in Zone 4 of Medicine, and in Zone 4 of the minor category Genetics & Heredity. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Epigenomics?
The latest impact factor listed by LetPub is 3.16; CiteScore 3.9, h-index 96.
How long does peer review take at Epigenomics?
Based on the dates recorded on 103 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 117 days (interquartile range 89–148 days); authors report an average review time of over 12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Epigenomics?
According to the journal's author guidelines: Abstract: ≤ 200 words; Reference style: Numbered, in order of citation. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Which databases index Epigenomics?
According to LetPub and DOAJ records, Epigenomics is indexed in SCIE and Scopus.
Is Epigenomics open access, and what is the APC?
Epigenomics is a hybrid journal. For open-access publication: APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .